Company intelligence / Profile preview

Adjuvance Technologies

Lincoln, Nebraska, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

Adjuvance Technologies develops next-generation semi-synthetic and synthetic vaccine adjuvants—primarily the TQL1055 triterpene saponin analog—which show improved immune response and reduced toxicity compared to traditional QS‑21. The company’s focus includes infectious disease vaccines and immuno-oncology applications. As of the most recent updates, their lead candidate TQL1055 was in pre-clinical development with patent protection granted for its composition and use. No published clinical results yet.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Vaccine adjuvants (notably saponin-based)Vaccines
Industry: Biotech

Drug pipeline

2 assets

TQL-1055

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Adjuvance Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adjuvance Technologies.

Explore the full profile